Dewan Institute of Intellectual Property Rights

Internationally renowned, highly experienced & knowledgeable faculty

DIIPR’s faculty comprises highly knowledgeable advocates, patent & trademark attorneys, ex-Controllers and numerous guest lecturers of the highest calibre from India & internationally. All DIIPR faculty have worked in the industry for decades and are regular speakers and authorities in their own right at national and international IP conferences.

Our faculty places great emphasis on providing you with a practical understanding of the law. They will go through the nuances of the law with you and spell out the ‘dos and don’ts’. They will answer the questions that have confused you in the past and clarify any blurry concepts in a simple, easy to understand manner. They will equip you with the precise information you need on various IP matters to implement actively to benefit your business or career.

From answering your basic questions as a newcomer to the field to conducting advanced sessions for the seasoned IP professional, our faculty is passionate about teaching and look forward to welcoming you at DIIPR in the near future.

Test your IP Quotient

Start Test

Representative courses & seminars conducted by DIIPR faculty include

7th Global Intellectual Property Convention – Mumbai, INDIA, January 2015.

Dr Mohan Dewan - Speaker, “IP Cases and related judgments”, Moderator of Plenary Session with theme “Enforcement of IP (Judiciary & Customs).”

World IP Forum – New Delhi, INDIA, January 2015.

Dr Mohan Dewan – Moderator of session titled “Significant changes in IP world for IT & Telecom.”

LITCON, Chennai, December 2014

Dr Mohan Dewan, Chairman of LITCON (Conference for IP Litigation) & Speaker on topic “Devising Winning Strategies for Protection and Enforcement of your IPR.”

3rd International Conference & Exhibition on Biowaivers and Biosimilars, Hyderabad, October 2014

Dr Mohan Dewan, Key Note Speaker “The Positive Role of Intellectual Property in the Creation of Cost Effective and Affordable Biosimilars.”